tapinarof (Vtama) Report issue

Small molecule Approved FDA First in Class
AACT MeSH PubChem

Active Ingredient History

NOW
  • Now
Tapinarof, also known as benvitimod and sold under the brand name Vtama, is a medication used for the treatment of plaque psoriasis. The medication is applied to the skin. Besides its use in medicine, tapinarof is a naturally occurring compound found in bacterial symbionts of nematodes which has antibiotic properties.   Wikipedia

Chemistry

  • SMILES: CC(C)c1c(O)cc(/C=C/c2ccccc2)cc1O
  • InChIKey: ZISJNXNHJRQYJO-CMDGGOBGSA-N
  • Mol. Mass: 254.33
  • ALogP: 4.39
  • ChEMBL Molecule:
    tapinarof  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Alternative names

2-isopropyl-5-(2-phenylethenyl)benzene-1,3-diol | 5-(2-phenylethenyl)-2-isopropyl-1,3-benzenediol | benvitimod | gsk2894512 | wbi-1001

Organizations (12)

Research & Development (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (1)


 

Psoriasis (approved 2022)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Dermatitis, Atopic (Phase 3)

Psoriasis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial Organizations: 12

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue